Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7875913 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Part A: RO7875913 | EXPERIMENTAL | Participants will receive RO7875913. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo. |
| Part B: RO7875913 with cevostamab | EXPERIMENTAL | Participants will recieve RO7875913 with cevostamab. |
| Name | Type | Description |
|---|---|---|
| RO7875913 | DRUG | Participants will receive RO7875913 as per the schedule described in the protocol. |
| Placebo | DRUG | Participants will receive placebo as per the schedule described in the protocol. |
| Cevostamab | DRUG | Participants will receive cevostamab as per the schedule described in the protocol |
Inclusion Criteria: General: * Agreement to adhere to the contraception requirements Part A: * Body weight \> 40 kilogram (kg) with a body mass index of 18-30 kg per meter square (kg/m\^2) Part B: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy of at ...
Top 20 of 25 competitors
RO7875913 is an investigational small molecule being developed by Roche Holding AG for relapsed multiple myeloma. It is in Phase 1 clinical development and is also being studied in healthy participants. It has not been approved by the FDA and remains an experimental therapy under clinical evaluation.
RO7875913 is being studied for relapsed and refractory multiple myeloma, a blood cancer that has returned or stopped responding to prior treatment. The Phase 1 program evaluates RO7875913 both alone in healthy participants and in combination with cevostamab in participants with relapsed or refractory multiple myeloma.
RO7875913 is developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor running the clinical program for this investigational small molecule in relapsed multiple myeloma and in healthy volunteer studies.
RO7875913 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The program includes one active trial that is no longer recruiting participants, with a planned enrollment of 240 people.
RO7875913 is being evaluated in the Phase 1 trial NCT07342114, titled a study of the effects of RO7875913 in healthy participants and of RO7875913 with cevostamab in participants with relapsed or refractory multiple myeloma. The trial is active but not recruiting, is placebo controlled and double blind, and enrolls 240 participants in New Zealand.
Yes. The Phase 1 trial NCT07342114 evaluates RO7875913 in combination with cevostamab in participants with relapsed or refractory multiple myeloma, while also assessing RO7875913 alone in healthy participants. The study is placebo controlled, double blind, randomized, and is being conducted in New Zealand.